High-dose selenium substitution in sepsis: a prospective randomized clinical trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F11%3A10089" target="_blank" >RIV/00216208:11110/11:10089 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/11:10089
Result on the web
<a href="http://dx.doi.org/10.1007/s00134-011-2153-0" target="_blank" >http://dx.doi.org/10.1007/s00134-011-2153-0</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
High-dose selenium substitution in sepsis: a prospective randomized clinical trial
Original language description
Systemic inflammatory response syndrome (SIRS) and sepsis remain the leading cause of death in the critically ill. A reduction in the antioxidant capacity, including selenoenzymes that are dependent on selenium (Se), could be a contributing factor. Se supplementation in septic patients have yielded conflicting results. We hypothesized that a high-dose Se supplementation would (1) improve markers of inflammation, nutrition and antioxidant defence, and (2) decrease mortality. This prospective, randomized,open-label, single-centre clinical trial included 150 patients with SIRS/sepsis and a SOFA score of > 5. Patients in the Se+ group (n = 75) received Se for 14 days (1,000 mu g on day 1,500 mu g/day on days 2-14).
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FP - Other medical fields
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)